Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT-P2
- Sponsors Eli Lilly and Company
- 01 Oct 2022 Results of post hoc analysis from SPIRIT-P1, SPIRIT-P2 assessing efficacy, safety, and immunogenicity published in the Clinical Rheumatology
- 07 Apr 2022 Results assessing the updated safety profile of ixekizumab up to 3 years in patients with PsA from 4 trials (NCT01695239, NCT02349295, NCT02584855, NCT03151551) published in the Annals of the Rheumatic Diseases
- 09 Nov 2021 Results from the post-hoc analysis of pooled data from SPIRIT-P1 and -P2 studies evaluating the efficacy, presented at the ACR Convergence 2021